Update on oxalate crystal disease

Current Rheumatology Reports

Volumn 15, Issue 7, 2013, Pages

  Lorenz, Elizabeth C ^a   Michet, Clement J ^a   Milliner, Dawn S ^a   Lieske, John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Calcium oxalate; Crystalline arthropathy; Diagnosis; Enteric hyperoxaluria; Oxalate crystal disease; Oxalosis; Primary hyperoxaluria; Secondary hyperoxaluria; Treatment

Indexed keywords

CALCIUM OXALATE; COLCHICINE; LANTHANUM CARBONATE; PROBIOTIC AGENT; PYRIDOXINE;

ARTHRITIS; ARTICLE; CELL PROLIFERATION; CLINICAL FEATURE; CYTOPENIA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENETIC ASSOCIATION; HEMODIALYSIS; HUMAN; HYPEROXALURIA; INTERNALIZATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MYOPATHY; NEUROPATHY; NONHUMAN; OXALATE ARTHRITIS; OXALOBACTER FORMIGENES; OXALOSIS 1; PATHOPHYSIOLOGY; SYNOVIAL FLUID; TREATMENT PLANNING; COMPLICATION; METABOLISM; REVIEW;

ARTHRITIS; CALCIUM OXALATE; HUMANS; HYPEROXALURIA; SYNOVIAL FLUID;

EID: 84877114629     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0340-4     Document Type: Article

References (101)

1. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264-71.
2. van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in the netherlands: Prevalence and outcome. Nephrol Dial Transplant. 2003;18(2):273-9. (Pubitemid 36181676)
3. •• Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8(8):467-75. An excellent review of primary hyperoxaluria.
4. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. International registry for primary hyperoxaluria. Am J Nephrol. 2005;25(3):290-6. (Pubitemid 41202753)
5. •• Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;87(3):392-9. Initial description of the genetic mutations responsible for primary hyperoxaluria type 3.
6. • Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, et al. Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011;6(9):2289-95. A study suggesting that genetic mutations involved in primary hyperoxaluria type 3 may also be a risk factor for idiopathic kidney stones.
7. Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT. 4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition. Biochim Biophys Acta. 2012;1822(10):1544-52.
8. Cornelis T, Bammens B, Lerut E, Cosyn L, Goovaerts G, Westhovens R, et al. AA amyloidosis due to chronic oxalate arthritis and vasculitis in a patient with secondary oxalosis after jejunoileal bypass surgery. Nephrol Dial Transplant. 2008;23(10):3362-4.
9. Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. N Engl J Med. 1977;296(6):298-301. (Pubitemid 8047241)
10. •• Kumar R, Lieske JC, Collazo-Clavell ML, Sarr MG, Olson ER, Vrtiska TJ, et al. Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. Surgery. 2011;149(5):654-61. A study decribing the incidence of increased oxalate absorption following bariatric surgery.
11. Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. Gastroenterology. 1976;70(6):1096-100.
12. Hylander E, Jarnum S, Jensen HJ, Thale M. Enteric hyperoxaluria: Dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease. Scand J Gastroenterol. 1978;13(5):577-88. (Pubitemid 9003936)
13. Hueppelshaeuser R, von Unruh GE, Habbig S, Beck BB, Buderus S, Hesse A, et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn's disease. Pediatr Nephrol. 2012;27(7):1103-9.
14. Ciacci C, Spagnuolo G, Tortora R, Bucci C, Franzese D, Zingone F, et al. Urinary stone disease in adults with celiac disease: Prevalence, incidence and urinary determinants. J Urol. 2008;180(3):974-9.
15. Cartery C, Faguer S, Karras A, Cointault O, Buscail L, Modesto A, et al. Oxalate nephropathy associated with chronic pancreatitis. Clin J Am Soc Nephrol. 2011;6(8):1895-902.
16. • Rahman N, Hitchcock R. Case report of paediatric oxalate urolithiasis and a review of enteric hyperoxaluria. J Pediatr Urol. 2010;6(2):112-6. A review of enteric hyperoxaluria in children.
17. Nasr SH, D'Agati VD, Said SM, Stokes MB, Largoza MV, Radhakrishnan J, et al. Oxalate nephropathy complicating roux-en-Y gastric bypass: An underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol. 2008;3(6):1676-83.
18. Sinha MK, Collazo-Clavell ML, Rule A, Milliner DS, Nelson W, Sarr MG, et al. Hyperoxaluric nephrolithiasis is a complication of roux-en-Y gastric bypass surgery. Kidney Int. 2007;72(1):100-7. (Pubitemid 47014438)
19. • Pang R, Linnes MP, O'Connor HM, Li X, Bergstralh E, Lieske JC. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology. 2012;80(2):250-4. A study outlining the limitations of a low-oxalate diet alone following bariatric surgery.
20. Penniston KL, Kaplon DM, Gould JC, Nakada SY. Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass. J Urol. 2009;182(5):2340-6.
21. Duffey BG, Pedro RN, Makhlouf A, Kriedberg C, Stessman M, Hinck B, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg. 2008;206(3):1145-53.
22. Froeder L, Arasaki CH, Malheiros CA, Baxmann AC, Heilberg IP. Response to dietary oxalate after bariatric surgery. Clin J Am Soc Nephrol. 2012;7(12):2033-40.
23. Ehlers SM, Posalaky Z, Strate RG, Quattlebaum FW. Acute reversible renal failure following jejunoileal bypass for morbid obesity: A clinical and pathological (EM) study of a case. Surgery. 1977;82:629-34. (Pubitemid 8226496)
24. Verani R, Nasir M, Foley R. Granulomatous interstitial nephritis after a jejunoileal bypass: An ultrastructural and histochemical study. Am J Nephrol. 1989;9(1):51-5. (Pubitemid 19102718)
25. Sarica K, Akarsu E, Erturhan S, Yagci F, Aktaran S, Altay B. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor. Obesity (Silver Spring). 2008;16(7):1579-84. (Pubitemid 351915115)
26. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430-2.
27. Hatch M, Freel RW. Intestinal transport of an obdurate anion: Oxalate. Urol Res. 2005;33(1):1-16. (Pubitemid 40487187)
28. Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. Reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 2006;69(4):691-8. (Pubitemid 43237638)
29. Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. J Am Soc Nephrol. 1999;10 Suppl 14:S324-8.
30. Jacobsen D, Hewlett TP, Webb R, Brown ST, Ordinario AT, McMartin KE. Ethylene glycol intoxication: Evaluation of kinetics and crystalluria. Am J Med. 1988;84(1):145-52.
31. Brent J, McMartin K, Phillips S, Burkhart KK, Donovan JW, Wells M, et al. Fomepizole for the treatment of ethylene glycol poisoning. Methylpyrazole for toxic alcohols study group. N Engl J Med. 1999;340(11):832-8. (Pubitemid 29142626)
32. Sanz P, Reig R. Clinical and pathological findings in fatal plant oxalosis. A review. The American journal of forensic medicine and pathology. 1992;13(4):342-5.
33. Barceloux DG. Rhubarb and oxalosis (rheum species). Dis Mon. 2009;55(6):403-11.
34. Lieske JC, Swift HS, Martin T, Patterson B, Toback FG. Renal epithelial cells rapidly bind and internalize calcium oxalate monohydrate crystals. ProcNatlAcadSci, USA. 1994;91:6987-91. (Pubitemid 24226787)
35. Lieske JC, Toback FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol. 1993;264:F800-F7.
36. Hammes MS, Lieske JC, Pawar S, Spargo BH, Toback FG. Calcium oxalate monohydrate crystals stimulate gene expression in renal epithelial cells. Kidney Int. 1995;48:501-9.
37. Lieske JC, Walsh-Reitz MM, Toback FG. Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. AmJPhysiol. 1992;262:F622-F30.
38. Lieske JC, Deganello S, Toback FG. Cell-crystal interactions and kidney stone formation. Nephron. 1999;81(S1):S8-S17. (Pubitemid 29015462)
39. Khan SR, Finlayson B, Hackett RL. Scanning electron microscopy of calcium oxalate crystal formation in experimental nephrolithiasis. LabInvest. 1979;41:504-10. (Pubitemid 10168517)
40. Dykstra MJ, Hackett RL. Ultrastructural events in early calcium oxalate crystal formation in rats. Kidney Int. 1979;15:640-50. (Pubitemid 9255243)
41. Khan SR, Finlayson B, Hackett RL. Histologic study of the early events in oxalate induced intranephronic calculosis. InvestUrol. 1979;17:199-202. (Pubitemid 10105276)
42. Lieske JC, Spargo BH, Toback FG. Endocytosis of calcium oxalate crystals and proliferation of renal tubular epithelial cells in a patient with type 1 primary hyperoxaluria. J Urol. 1992;148(5):1517-9.
43. •• Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, et al. Primary hyperoxaluria type 1: Indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27(5):1729-36. A review of methods used to diagnose primary hyperoxaluria.
44. Kohn NN, Hughes RE, Mc Jr CD, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: The «pseudogout syndrome». II. Identification of crystals. Ann Intern Med. 1962;56:738-45.
45. Sarraf P, Kay J, Reginato AM. Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. Curr Rheumatol Rep. 2008;10(3):235-48.
46. Verbruggen LA, Bourgain C, Verbeelen D. Late presentation and microcrystalline arthropathy in primary hyperoxaluria. Clin Exp Rheumatol. 1989;7(6):631-3. (Pubitemid 20100990)
47. Rosenthal A, Ryan LM, McCarty DJ. Arthritis associated with calcium oxalate crystals in an anephric patient treated with peritoneal dialysis. Jama. 1988;260(9):1280-2.
48. Maldonado I, Prasad V, Reginato AJ. Oxalate crystal deposition disease. Curr Rheumatol Rep. 2002;4(3):257-64.
49. •• Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, et al. Bone metabolism in oxalosis: A single-center study using new imaging techniques and biomarkers. Pediatr Nephrol. 2010;25(6):1081-9. A study of bone imaging and FGF23 levels in patients with primary hyperoxaluria.
50. El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, et al. Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop. 2008;2(3):205-10.
51. Behnke B, Kemper MJ, Kruse HP, Muller-Wiefel DE. Bone mineral density in children with primary hyperoxaluria type I. Nephrol Dial Transplant. 2001;16(11):2236-9. (Pubitemid 33062150)
52. Aydin NE, Usta U. Oxalate deposition in tissues. Nephrol Dial Transplant. 2004;19(5):1323-4. (Pubitemid 38628164)
53. Bakshi NA, Al-Zahrani H. Bone marrow oxalosis. Blood. 2012;120(1):8.
54. Tapia G, Navarro JT, Navarro M. Leukoerythroblastic anemia due to oxalosis with extensive bone marrow involvement. Am J Hematol. 2008;83(6):515-6. (Pubitemid 351742805)
55. Mookadam F, Smith T, Jiamsripong P, Moustafa SE, Monico CG, Lieske JC, et al. Cardiac abnormalities in primary hyperoxaluria. Circ J. 2010;74(11):2403-9.
56. Van Driessche L, Dhondt A, De Sutter J. Heart failure with mitral valve regurgitation due to primary hyperoxaluria type 1: Case report with review of the literature. Acta Cardiol. 2007;62(2):202-6. (Pubitemid 46649240)
57. •• Blackmon JA, Jeffy BG, Malone JC, Knable Jr AL. Oxalosis involving the skin: Case report and literature review. Arch Dermatol. 2011;147(11):1302-5. A review of how oxalosis affects the skin.
58. Fielder AR, Garner A, Chambers TL. Ophthalmic manifestations of primary oxalosis. Br J Ophthalmol. 1980;64(10):782-8. (Pubitemid 11238344)
59. Munir WM, Sharma MC, Li T, Dealba F, Goldstein DA. Retinal oxalosis in primary hyperoxaluria type 1. Retina. 2004;24(6):974-6. (Pubitemid 39657501)
60. Small KW, Letson R, Scheinman J. Ocular findings in primary hyperoxaluria. Arch Ophthalmol. 1990;108(1):89-93. (Pubitemid 20031418)
61. Bilbao JM, Berry H, Marotta J, Ross RC. Peripheral neuropathy in oxalosis. A case report with electron microscopic observations. Can J Neurol Sci. 1976;3(1):63-7.
62. Galloway G, Giuliani MJ, Burns DK, Lacomis D. Neuropathy associated with hyperoxaluria: Improvement after combined renal and liver transplantations. Brain Pathol. 1998;8(2):247-51. (Pubitemid 28186062)
63. Hall BM, Walsh JC, Horvath JS, Lytton DG. Peripheral neuropathy complicating primary hyperoxaluria. J Neurol Sci. 1976;29(2-4):343-9.
64. Moorhead PJ, Cooper DJ, Timperley WR. Progressive peripheral neuropathy in patient with primary hyperoxaluria. Br Med J. 1975;2(5966):312-3.
65. Mitsimponas KT, Wehrhan T, Falk S, Wehrhan F, Neukam FW, Schlegel KA. Oral findings associated with primary hyperoxaluria type I. J Craniomaxillofac Surg. 2012;40(8):e301-6.
66. Panis V, Tosios KI, Gagari E, Griffin TJ, Damoulis PD. Severe periodontitis in a patient with hyperoxaluria and oxalosis: A case report and review of the literature. J Periodontol. 2010;81(10):1497-504.
67. Rinksma AJ, Oosterhuis JW, Wolvius EB, van der Wal KG. Oral manifestations of oxalosis: A case report and review of the literature. J Oral Maxillofac Surg. 2008;66(9):1953-6.
68. Fishbein GA, Micheletti RG, Currier JS, Singer E, Fishbein MC. Atherosclerotic oxalosis in coronary arteries. Cardiovasc Pathol. 2008;17(2):117-23. (Pubitemid 351337659)
69. Tanriover B, Mejia A, Foster SV, Mubarak A. Primary hyperoxaluria involving the liver and hepatic artery: Images of an aggressive disease. Kidney Int. 2010;77(7):651.
70. Milliner DS, Eickholt JT, Bergstralh E, Wilson DM, Smith LH. Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. New Engl J Med. 1994;331:1553-8. (Pubitemid 24366902)
71. Mandell I, Krauss E, Millan JC. Oxalate-induced acute renal failure in Crohn's disease. AmJMed. 1980;69:628-32. (Pubitemid 10018722)
72. Earnest DL, Johnson G, Williams HE, Admirand WH. Hyperoxaluria in patients with ileal resection: An abnormality in dietary oxalate absorption. Gastroenterology. 1974;66(6):1114-22.
73. Andersson H, Bosaeus I. Hyperoxaluria in malabsorptive states. Urol Int. 1981;36(1):1-9. (Pubitemid 11103899)
74. • Mulay SR, Kulkarni OP, Rupanagudi KV, Migliorini A, Darisipudi MN, Vilaysane A, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J Clin Invest. 2013;123(1):236-46. A study demonstrating how calcium oxalate crystals induce IL-1β secretion.
75. Rankin AC, Walsh SB, Summers SA, Owen MP, Mansell MA. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant. 2008;8(8):1755-8.
76. Robijn S, Vervaet BA, Hoppe B, D'Haese PC, Verhulst A. Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats. J Urol 2012 Dec 7.
77. Lieske JC, Regnier C, Dillon JJ. Use of sevelamer hydrochloride as an oxalate binder. J Urol. 2008;179(4):1407-10.
78. Lieske JC, Goldfarb DS, De Simone C, Regnier C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 2005;68(3):1244-9. (Pubitemid 43246443)
79. •• Lieske JC, Tremaine WJ, De Simone C, O'Connor HM, Li X, Bergstralh EJ, et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int. 2010;78(11):1178-85. A study investigating the role of diet and priobiotics on urinary oxalate excretion in patients with hyperoxaluria.
80. Gibbs DA, Watts RW. The action of pyridoxine in primary hyperoxaluria. Clin Sci. 1970;38(2):277-86.
81. Watts RW, Veall N, Purkiss P, Mansell MA, Haywood EF. The effect of pyridoxine on oxalate dynamics in three cases of primary hyperoxaluria (with glycollic aciduria). Clin Sci. 1985;69(1):87-90. (Pubitemid 15032480)
82. • Fargue S, Lewin J, Rumsby G, Danpure CJ. Four of the most common mutations in primary hyperoxaluria type 1 unmask the cryptic mitochondrial targeting sequence of alanine:glyoxylate aminotransferase encoded by the polymorphic minor allele. J Biol Chem 2012 Dec 10. A study showing how specific mutations result in mistargeting of the the peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT) to mitochondria in primary hyperoxaluria.
83. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. 2005;67(5):1704-9. (Pubitemid 40577704)
84. Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int. 2006;70(9):1642-8. (Pubitemid 44607001)
85. Franssen CF. Oxalate clearance by haemodialysis-a comparison of seven dialysers. Nephrol Dial Transplant. 2005;20(9):1916-21. (Pubitemid 41222608)
86. Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, et al. Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol. 1996;10(4):488-92. (Pubitemid 26261608)
87. Hoppe B, Langman CB. A united states survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol. 2003;18(10):986-91. (Pubitemid 37236210)
88. Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria-the german experience. Am J Nephrol. 2005;25(3):276-81. (Pubitemid 41202751)
89. • Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: Strategy for organ transplantation. Curr Opin Organ Transplant. 2010;15(5):590-3. An overview of transplant options for patients with primary hyeroxaluria.
90. •• Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al. Transplantation outcomes in primary hyperoxaluria. Am J Transplant. 2010;10(11):2493-501. A study examining the outcome of transplantation in patients with primary hyperoxaluria over the past decade.
91. Monico CG, Milliner DS. Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. 2001;7(11):954-63. (Pubitemid 33085784)
92. Allison MJ, Dawson KA, Mayberry WR, Foss JG. Oxalobacter formigenes gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. Arch Microbiol. 1985;141(1):1-7. (Pubitemid 15139551)
93. Grujic D, Salido EC, Shenoy BC, Langman CB, McGrath ME, Patel RJ, et al. Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria. Am J Nephrol. 2009;29(2):86-93.
94. •• Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461-9. Examination of the beneficial effect of Oxalobacter in mice with primary hyperoxaluria.
95. Sidhu H, Schmidt ME, Cornelius JG, Thamilselvan S, Khan SR, Hesse A, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium oxalobacter formigenes: Possible prevention by gut recolonization or enzyme replacement therapy. J Am Soc Nephrol. 1999;10 Suppl 14:S334-40.
96. Hatch M, Freel RW. Renal and intestinal handling of oxalate following oxalate loading in rats. Am J Nephrol. 2003;23(1):18-26. (Pubitemid 35316760)
97. Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, et al. Oxalobacter formigenes: A potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 2006;70(7):1305-11. (Pubitemid 44435182)
98. •• Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, et al. Efficacy and safety of oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. Nephrology, dialysis, transplantation: Official publication of the european dialysis and transplant association. European Renal Association. 2011;26(11):3609-15. Lack of effect of Oxalobacter on urinary oxalate excretion in patients with primary hyperoxaluria.
99. • Salido E, Rodriguez-Pena M, Santana A, Beattie SG, Petry H, Torres A. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol Ther. 2011;19(5):870-5. A study describing the successful treatment of hyperoxaluria in mice using gene transfer.
100. Hopper ED, Pittman AM, Fitzgerald MC, Tucker CL. In vivo and in vitro examination of stability of primary hyperoxaluria-associated human alanine:Glyoxylate aminotransferase. J Biol Chem. 2008;283(45):30493-502.
101. Lumb MJ, Birdsey GM, Danpure CJ. Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem J. 2003;374(Pt 1):79-87. (Pubitemid 37046931)